IP Library Granted Patent US 12,673,159
Granted Patent B2
US 12,673,159 · App. 18/060,273 · Granted Jul 7, 2026

Mealtime delivery of correction boluses

Inventors: Anirban Roy (Agoura Hills, CA); Benyamin Grosman (Winnetka, CA); Neha J. Parikh (West Hills, CA)
Assignee: Medtronic MiniMed, Inc.
A61M5/1723A61B5/14532A61B5/14865A61B5/7475G16H20/17G16H40/63A61M2005/14208A61M2230/201
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,673,159
App. No.
18/060,273
Filed
Nov 30, 2022
Granted
Jul 7, 2026
Kind
B2
Art Unit
3783
USPC
604/504
Abstract

Disclosed herein are techniques related to delivery of correction boluses. In some embodiments, the techniques involve obtaining data indicative of an ongoing glycemic response to a meal; and causing delivery of one or more correction boluses to at least partially counteract the ongoing glycemic response to the meal.

Claims (50)

1 . A system comprising:

one or more processors; and

one or more processor-readable media storing instructions which, when executed by the one or more processors, cause performance of:

obtaining data indicative of an ongoing glycemic response to a meal, the data comprising glucose concentration measurements evaluated in combination with estimated plasma insulin concentration values; and

causing delivery of one or more correction boluses to at least partially counteract the ongoing glycemic response to the meal, the correction boluses being [i] delivered instead of or in addition to a meal bolus delivered for the meal and [ii] delivered after detection of the ongoing glycemic response to the meal.

2 . The system of claim 1 , wherein causing delivery of the one or more correction boluses comprises:

reducing a target glucose value from a first glucose value to a second glucose value;

determining an amount of a correction bolus based on a difference between a current glucose value and the reduced target glucose value; and

increasing the reduced target glucose value from the second glucose value to the first glucose value.

3 . The system of claim 2 , wherein the target glucose value is separate from a target glucose value used for basal dosages.

4 . The system of claim 1 , wherein causing delivery of the one or more correction boluses comprises:

reducing a parameter from a first parameter value to a second parameter value;

determining an augmented amount of a correction bolus based on the reduced parameter; and

increasing the reduced parameter from the second parameter value to the first parameter value.

5 . The system of claim 4 , wherein the parameter is an insulin sensitivity factor.

6 . The system of claim 1 , wherein the one or more processor-readable media further store instructions which, when executed by the one or more processors, cause performance of:

after causing delivery of the one or more correction boluses, causing delivery of a meal bolus.

7 . The system of claim 6 , wherein causing delivery of the meal bolus comprises:

determining a potential amount for the meal bolus;

determining a total amount of insulin delivered as the one or more correction boluses; and

determining a reduced amount for the meal bolus based on subtracting, from the potential amount for the meal bolus, the total amount of insulin delivered as the one or more correction boluses.

8 . The system of claim 1 , wherein the data indicative of the ongoing glycemic response to the meal comprises an output generated by a meal detection model.

9 . The system of claim 8 , wherein the output is generated based on applying the meal detection model to a plurality of glucose concentration values corresponding with a plurality of plasma insulin concentration estimations.

10 . The system of claim 1 , wherein causing delivery of the one or more correction boluses comprises communicating one or more signals to an insulin delivery device.

11 . The system of claim 1 , wherein causing delivery of the one or more correction boluses comprises communicating one or more signals to an actuator associated with an insulin reservoir.

12 . A processor-implemented method comprising:

obtaining data indicative of an ongoing glycemic response to a meal, the data comprising glucose concentration measurements evaluated in combination with estimated plasma insulin concentration values; and

causing delivery of one or more correction boluses to at least partially counteract the ongoing glycemic response to the meal, the correction boluses being [i] delivered instead of or in addition to a meal bolus delivered for the meal and [ii] delivered after detection of the ongoing glycemic response to the meal.

13 . The processor-implemented method of claim 12 , wherein causing delivery of the one or more correction boluses comprises:

reducing a target glucose value from a first glucose value to a second glucose value;

determining an amount of a correction bolus based on a difference between a current glucose value and the reduced target glucose value; and

increasing the reduced target glucose value from the second glucose value to the first glucose value.

14 . The processor-implemented method of claim 13 , wherein the target glucose value is separate from a target glucose value used for basal dosages.

15 . The processor-implemented method of claim 12 , wherein causing delivery of the one or more correction boluses comprises:

reducing a parameter from a first parameter value to a second parameter value;

determining an amount of a correction bolus based on the reduced parameter; and

increasing the reduced parameter from the second parameter value to the first parameter value.

16 . The processor-implemented method of claim 15 , wherein the parameter is an insulin sensitivity factor.

17 . The processor-implemented method of claim 12 , further comprising:

after causing delivery of the one or more correction boluses, causing delivery of a meal bolus.

18 . The processor-implemented method of claim 17 , wherein causing delivery of the meal bolus comprises:

determining a total amount of insulin delivered as the one or more correction boluses; and

determining an amount of the meal bolus based on subtracting the total amount of insulin delivered as the one or more correction boluses.

19 . One or more processor-readable media storing instructions which, when executed by one or more processors, cause performance of:

obtaining data indicative of an ongoing glycemic response to a meal, the data comprising glucose concentration measurements evaluated in combination with estimated plasma insulin concentration values; and

causing delivery of one or more correction boluses to at least partially counteract the ongoing glycemic response to the meal, the correction boluses being [i] delivered instead of or in addition to a meal bolus delivered for the meal and [ii] delivered after detection of the ongoing glycemic response to the meal.

20 . The one or more processor-readable media of claim 19 , further storing instructions which, when executed by the one or more processors, cause performance of:

reducing a target glucose value from a first glucose value to a second glucose value;

determining an amount of a correction bolus based on a difference between a current glucose value and the reduced target glucose value; and

increasing the reduced target glucose value from the second glucose value to the first glucose value.

Assignments (2)
SECURITY INTEREST Recorded Jan 16, 2026
From: MEDTRONIC MINIMED, INC.; COMPANION MEDICAL, INC.
To: CITIBANK, N.A.
Reel/Frame 074394/0237 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 30, 2022
From: ROY, ANIRBAN; GROSMAN, BENYAMIN; PARIKH, NEHA J.
To: MEDTRONIC MINIMED, INC.
Reel/Frame 061926/0114 →
Continuity (2)
Provisional Application 63285042 · Dec 1, 2021
Related Publication 20230166036A1 · Jun 1, 2023
References Cited (63)
US 8560082B2 · Wei · 2013 [cited by applicant]
US 9398869B2 · Kovatchev et al. · 2016 [cited by applicant]
US 9827371B2 · Soru et al. · 2017 [cited by applicant]
US 9867937B2 · Saint et al. · 2018 [cited by applicant]
US 10357606B2 · Rosinko et al. · 2019 [cited by applicant]
US 10610154B2 · Kovatchev et al. · 2020 [cited by applicant]
US 10792423B2 · Chen et al. · 2020 [cited by applicant]
US 11024429B2 · Patek et al. · 2021 [cited by applicant]
US 11430557B2 · Mougiakakou et al. · 2022 [cited by applicant]
US 11806137B2 · Roy et al. · 2023 [cited by applicant]
US 20100298685A1 · Hayter et al. · 2010 [cited by applicant]
US 20120059673A1 · Cohen et al. · 2012 [cited by applicant]
US 20140066889A1 · Grosman · 2014 [cited by examiner]
US 20160354543A1 · Cinar et al. · 2016 [cited by applicant]
US 20170185748A1 · Budiman et al. · 2017 [cited by applicant]
US 20180169334A1 · Grosman · 2018 [cited by examiner]
US 20180174675A1 · Roy · 2018 [cited by examiner]
US 20190374137A1 · Kovatchev et al. · 2019 [cited by applicant]
US 20200101221A1 · Lintereur · 2020 [cited by examiner]
US 20200197605A1 · Haidar · 2020 [cited by applicant]
US 20200214629A1 · Kovatchev et al. · 2020 [cited by applicant]
US 20210001038A1 · Rosinko · 2021 [cited by applicant]
US 20210050085A1 · Hayter · 2021 [cited by examiner]
US 20210077719A1 · Cardinali et al. · 2021 [cited by applicant]
US 20210093782A1 · Saint et al. · 2021 [cited by applicant]
US 20210093783A1 · Lintereur · 2021 [cited by examiner]
US 20210154405A1 · Kearns et al. · 2021 [cited by applicant]
US 20210186417A1 · Braig et al. · 2021 [cited by applicant]
US 20210205534A1 · Jepson et al. · 2021 [cited by applicant]
US 20210244880A1 · Lee et al. · 2021 [cited by applicant]
US 20210259590A1 · Metzmaker et al. · 2021 [cited by applicant]
US 20210361864A1 · Lintereur et al. · 2021 [cited by applicant]
US 20220062548A1 · Zheng et al. · 2022 [cited by applicant]
US 20220062553A1 · Constantin et al. · 2022 [cited by applicant]
US 20220168505A1 · Li et al. · 2022 [cited by applicant]
US 20220233773A1 · Rueda et al. · 2022 [cited by applicant]
US 20220241500A1 · Jiang et al. · 2022 [cited by applicant]
US 20220257859A1 · Grosman et al. · 2022 [cited by applicant]
US 20220323676A1 · Krey et al. · 2022 [cited by applicant]
US 20230165490A1 · Roy et al. · 2023 [cited by applicant]
US 20230277097A1 · Roy et al. · 2023 [cited by applicant]
EP 2400882B1 · 2017 [cited by applicant]
WO 2020230123A1 · 2020 [cited by applicant]
Cinar A., et al., “Incorporating Unannounced Meals and Exercise in Adaptive Learning of Personalized Models for Multivariable Artificial Pancreas Systems,” Journal of Diabetes Science and Technology, Jul. 2018, vol. 12(… [cited by applicant]
International Search Report and Written Opinion dated Mar. 31, 2023 in PCT Application No. PCT/US2022/080777. [cited by applicant]
Boughton, C.K. et al., “Fully Automated Closed-loop Glucose Control Compared With Standard Insulin Therapy in Adults With Type 2 Diabetes Requiring Dialysis: an Open-label, Randomized Crossover Trial,” Nature Medicine, … [cited by applicant]
Boughton, C.K., et al., Fully Closed-loop Insulin Delivery—Are We Nearly There Yet?, The Lancet. Digital health, Nov. 2021, vol. 3, No. 11, pp. e689-e690. [cited by applicant]
Boughton, C.K., et al., “Fully Closed-loop Insulin Delivery in Inpatients Receiving Nutritional Support: a Two-centre, Open-label, Randomised Controlled Trial,” The lancet. Diabetes& Endocrinology, May 2019, vol. 7,… [cited by applicant]
For Clinicians “A General Introduction and guide to AndroidAPS”, 8 pages. [cited by applicant]
Forlenza, G. P., et al., “Fully Closed-Loop Multiple Model Probabilistic Predictive Controller Artificial Pancreas Performance in Adolescents and Adults in a Supervised Hotel Setting,” Diabetes Technology & Therapeu… [cited by applicant]
Garcia-Tirado, J. et al., “Advanced Closed-Loop Control System Improves Postprandial Glycemic Control Compared With a Hybrid Closed-Loop System Following Unannounced Meal,” Diabetes Care, 2021, vol. 44, No. 10, pp. 2379… [cited by applicant]
“Diabetes Technology Meeting 2021 Day #3 Highlights—Draft”, Closer Look, Nov. 3-6, 2021, pp. 1-14. [cited by applicant]
Loutseiko, M. et al., “Closed-Loop Insulin Delivery Utilizing Pole Placement to Compensate for Delays in Subcutaneous Insulin Delivery,” Journal of Diabetes Science and Technology, Nov. 2011, vol. 5, No. 6, pp. 1342-135… [cited by applicant]
McDermid, E., “AI May Facilitate Fully Closed-loop Insulin Delivery,” Medicine Matters Diabetes, May 6, 2021, 3 Pages. [cited by applicant]
Sherr, J.L. et al., “Automated Insulin Delivery: Benefits, Challenges and Recommendations. A Consensus Report of the Joint Diabetes Technology Working Group of the European Association for the Study of Diabetes and the … [cited by applicant]
Templer, S., “Closed-Loop Insulin Delivery Systems: Past, Present, and Future Directions,” Frontiers in Endocrinology, Jun. 2022, vol. 13, No. 919942, 9 Pages. [cited by applicant]
International Preliminary Report on Patentability and Written Opinion dated Jun. 13, 2024 in PCT Application No. PCT/US2022/051586. [cited by applicant]
International Preliminary Report on Patentability and Written Opinion dated Jun. 13, 2024 in PCT Application No. PCT/US2022/080777. [cited by applicant]
Invitation To Pay Additional Fees and, Where Applicable, Protest Fee dated Mar. 29, 2023 in PCT Application No. PCT/US2022/051586. [cited by applicant]
International Search Report and Written Opinion dated May 30, 2023, in Application No. PCT/US2022/051586. [cited by applicant]
U.S. Notice of Allowance dated Jul. 26, 2023 in U.S. Appl. No. 18/314,791. [cited by applicant]
U.S. Non-Final Office Action dated Sep. 10, 2025 in U.S. Appl. No. 18/060,268. [cited by applicant]
U.S. Notice of Allowance dated Jan. 12, 2026 in U.S. Appl. No. 18/060,268. [cited by applicant]